Morgan Stanley Maintains Equal-Weight on GRAIL, Raises Price Target to $120
Morgan Stanley analyst Tejas Savant maintains GRAIL (NASDAQ:GRAL) with a Equal-Weight and raises the price target from $60 to $120.
Stocks · News reference
FDA Panel Endorses GRAIL Galleri Cancer Screening Tool
The FDA advisory committee voted in favor of GRAIL's Galleri multi-cancer early detection test, moving it closer to official approval.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
TD Cowen Maintains Buy on GRAIL, Raises Price Target to $180
TD Cowen analyst Dan Brennan maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $88 to $180.
GRAIL To Present New NHS-Galleri Trial Data At Early Detection Of Cancer Conference And ESMO Congress
UBS Maintains Buy on GRAIL, Raises Price Target to $175
UBS analyst Doug Schenkel maintains GRAIL (NASDAQ:GRAL) with a Buy and raises the price target from $105 to $175.